Ionis Pharmaceuticals

YTD

ALL

Trade Ionis Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T.

CEO

Brett P. Monia

CEOBrett P. Monia

Employees

1,402

Employees1,402

Headquarters

Carlsbad, California

HeadquartersCarlsbad, California

Founded

1989

Founded1989

Employees

1,402

Employees1,402

IONS Key Statistics

Market cap

9.01B

Market cap9.01B

Price-Earnings ratio

-15.61

Price-Earnings ratio-15.61

Dividend yield

—

Dividend yield—

Average volume

3.21M

Average volume3.21M

High today

$56.15

High today$56.15

Low today

$54.16

Low today$54.16

Open price

$55.97

Open price$55.97

Volume

2.15M

Volume2.15M

52 Week high

$86.74

52 Week high$86.74

52 Week low

$50.01

52 Week low$50.01

Stock Snapshot

Ionis Pharmaceuticals(IONS) stock is priced at $54.26, giving the company a market capitalization of 9.01B. It carries a P/E multiple of -15.61.

As of 2026-09-13, Ionis Pharmaceuticals(IONS) stock has fluctuated between $54.16 and $56.15. The current price stands at $54.26, placing the stock +0.2% above today's low and -3.4% off the high.

Ionis Pharmaceuticals(IONS) shares are trading with a volume of 2.15M, against a daily average of 3.21M.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $50.01 at its lowest and $86.74 at its peak.

IONS News

Simply Wall St 2d

Ionis Pharmaceuticals On Mixed Trial And FDA News While The Undervalued Narrative Holds - simplywall.st

...

Nasdaq 4d

Cathie Wood Is Loading Up on Ionis Pharmaceuticals Stock. Here's the Bet She's Making.

Key Points Cathie Wood has bought and sold the stock a lot, so don't follow her blindly. The company posted a loss in its last quarter, but revenue is growing...

TipRanks 4d

Ionis Pharmaceuticals price target lowered to $85 from $90 at Barclays

Barclays lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $85 from $90 and keeps an Overweight rating on the shares. The firm says the Novarti...

Analyst ratings

81%

of 27 ratings

Buy

81.5%

Hold

18.5%

Sell

More IONS News

TipRanks 5d

Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss

Ionis Pharmaceuticals, Inc. (IONS) shares dropped about 10% in premarket trading after a large cardiovascular trial of pelacarsen, a drug developed by Ionis and...

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Rocket Lab Corporation

Vertex Pharmaceuticals

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.